WINTON GROUP Ltd Boosts Stock Position in Roivant Sciences Ltd. $ROIV

WINTON GROUP Ltd increased its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 104.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 208,064 shares of the company’s stock after acquiring an additional 106,072 shares during the quarter. WINTON GROUP Ltd’s holdings in Roivant Sciences were worth $2,345,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Two Seas Capital LP lifted its stake in Roivant Sciences by 4.6% during the second quarter. Two Seas Capital LP now owns 10,598,040 shares of the company’s stock worth $119,440,000 after purchasing an additional 461,733 shares during the last quarter. Invesco Ltd. boosted its holdings in Roivant Sciences by 3.8% in the first quarter. Invesco Ltd. now owns 9,880,526 shares of the company’s stock valued at $99,695,000 after acquiring an additional 365,468 shares in the last quarter. BlackBarn Capital Partners LP increased its position in Roivant Sciences by 15.2% during the 1st quarter. BlackBarn Capital Partners LP now owns 4,750,000 shares of the company’s stock valued at $47,928,000 after purchasing an additional 625,000 shares during the period. Bank of New York Mellon Corp raised its holdings in Roivant Sciences by 12.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 4,506,400 shares of the company’s stock worth $50,787,000 after purchasing an additional 506,219 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Roivant Sciences in the 1st quarter worth about $31,988,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analysts Set New Price Targets

ROIV has been the topic of a number of research reports. Guggenheim restated a “buy” rating and set a $25.00 target price on shares of Roivant Sciences in a report on Friday, November 14th. JPMorgan Chase & Co. boosted their price objective on shares of Roivant Sciences from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Thursday, September 18th. Leerink Partners reiterated an “outperform” rating and set a $29.00 target price on shares of Roivant Sciences in a research note on Tuesday, November 11th. Jefferies Financial Group boosted their price target on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. Finally, Bank of America increased their price objective on Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a research report on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.56.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 539,650 shares of the stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $20.51, for a total value of $11,068,221.50. Following the transaction, the insider owned 33,653,756 shares of the company’s stock, valued at approximately $690,238,535.56. This represents a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel Allen Gold sold 1,300,000 shares of the firm’s stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $20.23, for a total value of $26,299,000.00. Following the completion of the transaction, the director directly owned 18,047,727 shares in the company, valued at $365,105,517.21. The trade was a 6.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 6,707,812 shares of company stock worth $121,101,540. 10.80% of the stock is owned by insiders.

Roivant Sciences Trading Down 2.7%

Shares of ROIV opened at $20.43 on Wednesday. The firm has a market cap of $14.21 billion, a PE ratio of -36.48 and a beta of 1.22. The firm has a fifty day simple moving average of $19.06 and a two-hundred day simple moving average of $14.51. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $21.48.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.